Hironori Yamaguchi

Hironori Yamaguchi

Auto-generated profile, based on publicly available information

Hironori Yamaguchi

Jichi Medical University, Tochigi, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2003
Verified
Journal Article
Closed access
DSDai Shida
Dai Shida
JKJoji Kitayama
Joji Kitayama
HYHironori Yamaguchi
Hironori Yamaguchi
YOYurai Okaji
Yurai Okaji
NTNelson Hirokazu Tsuno
Nelson Hirokazu Tsuno
HNHirokazu Nagawa
Hirokazu Nagawa

8 April 2003 in Bioelectromagnetics
Verified
Journal Article
Closed access
PDF file
HYHironori Yamaguchi
Hironori Yamaguchi
GTGiichirou Tsurita
Giichirou Tsurita
SUShoogo Ueno
Shoogo Ueno
SWSoichi Watanabe
Soichi Watanabe
KWKanako Wake
Kanako Wake
HNHirokazu Nagawa
Hirokazu Nagawa

1 January 2004 in Bioelectromagnetics
Verified
Journal Article
Closed access
PDF file
KHKEISUKE Hata
KEISUKE Hata
HYHironori Yamaguchi
Hironori Yamaguchi
GTGiichirou Tsurita
Giichirou Tsurita
SWSoichi Watanabe
Soichi Watanabe
KWKanako Wake
Kanako Wake
HNHirokazu Nagawa
Hirokazu Nagawa

1 February 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MAMasaki Aizawa
Masaki Aizawa
HIHironori Ishigami
Hironori Ishigami
HYHiroshi Yabusaki
Hiroshi Yabusaki
ANAtsushi Nashimoto
Atsushi Nashimoto
HIHaruhiko Imamoto
Haruhiko Imamoto
J(Japan Intraperitoneal Chemotherapy Study Group (JIPG)
Japan Intraperitoneal Chemotherapy Study Group (JIPG)
96 Background: The presence of free cancer cells in the peritoneal cavity has been known as a poor prognostic factor in gastric cancer patients. Intraperitoneal (IP) paclitaxel (PTX) provides powerful local effects in the peritoneal cavity, and we previously reported the efficacy and safety of a regimen combining IP PTX with S-1/PTX in gastric cancer patients with peritoneal metastasis. This multicenter phase II study was conducted to evaluate the efficacy of IP PTX plus S-1/PTX for gastric cancer with positive peritoneal cytology. Methods: Eligibility criteria included pathologically confirmed gastric adenocarcinoma, intraperitoneal free cancer cells confirmed by peritoneal washing cytology, and no evidence of overt distant metastasis including macroscopic peritoneal metastasis. Patients were administered IP PTX 20 mg/m2, intravenous PTX 50 mg/m2 on days 1 and 8, and S-1 80 mg/m2/day on days 1-14, q3 weeks. The primary endpoint was the 1-year overall survival (OS) rate. Secondary endpoints were response rate, negative conversion rate on peritoneal cytology and safety. Results: Thirty eight patients were enrolled and fully evaluated for OS and toxicity. The median number of courses was 12.5 (range 2-35). The 1-year OS rate was 84.2% (95 % confidence interval, 68.2-92.6%). Of 3 patients with target lesions, partial response and stable disease were obtained in 2 and 1 patient(s), respectively. The peritoneal cytology findings converted from positive to negative in 36 (94.7 %) patients. The incidences of grade 3/4 hematological and non-hematological toxicities were 45 % and 26 %, respectively. The frequent grade 3/4 toxicities included neutropenia (23%), leukopenia (7%) and anemia (8%). Regarding adverse events related to IP port, 2 patients developed swelling around the port site. Conclusions: IP PTX with S-1/PTX was suggested to be a promising option for gastric cancer with positive peritoneal cytology through the clearance of cancer cells in the peritoneal cavity. Clinical trial information: UMIN000002850.

1 April 2006 in The Breast
Verified
Journal Article
Closed access
HYHironori Yamaguchi
Hironori Yamaguchi
MIMakoto Ishikawa
Makoto Ishikawa
KHKazuhito Hatanaka
Kazuhito Hatanaka
TUToshimasa Uekusa
Toshimasa Uekusa
MIMasahiro Ishimaru
Masahiro Ishimaru
HNHirokazu Nagawa
Hirokazu Nagawa

1 March 2015
Verified
Journal Article
Closed access
YIYuuki Iida
Yuuki Iida
ESEiji Sunami
Eiji Sunami
Hiroharu YamashitaHiroharu Yamashita
Hiroharu Yamashita
MHMasaya Hiyoshi
Masaya Hiyoshi
SISoichiro Ishihara
Soichiro Ishihara
TWToshiaki Watanabe
Toshiaki Watanabe